Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11)

DOI: 10.1186/s40880-019-0375-7

Keywords: Metastatic breast cancer, Eribulin, Paclitaxel, Neuropathy, Quality of life, Functional assessment of cancer therapy-taxane questionnaires

Full-Text   Cite this paper   Add to My Lib

Abstract:

The online version of this article (10.1186/s40880-019-0375-7) contains supplementary material, which is available to authorized users

Full-Text